Annals of Surgery Open (Jun 2021)

Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma

  • Binkui Li, MD, PhD,
  • Jiliang Qiu, MD, PhD,
  • Yun Zheng, MD, PhD,
  • Yunxing Shi, MD,
  • Ruhai Zou, MD, PhD,
  • Wei He, MD, PhD,
  • Yichuang Yuan, MD,
  • Yuanping Zhang, MD,
  • Chenwei Wang, MD,
  • Zhiyu Qiu, MD,
  • Kai Li, MD,
  • Chengrui Zhong, MD,
  • Yunfei Yuan, MD

DOI
https://doi.org/10.1097/AS9.0000000000000057
Journal volume & issue
Vol. 2, no. 2
p. e057

Abstract

Read online

Objective:. To evaluate whether this conversion rate to resectability could be increased when patients are treated with transarterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) using oxaliplatin plus fluorouracil/leucovorin. Background:. Conventional TACE (c-TACE) is a common regimen for initially unresectable hepatocellular carcinoma (HCC), which converts to curative-intent resection in about 10% of those patients. It is urgent need to investigated better regimen for those patients. Methods:. The data of 83 initially unresectable HCC patients were examined, including 41 patients in the TACE-HAIC group and 42 patients in the c-TACE group. Their response rate, conversion rate to resection, survival outcome, and adverse events were compared. Results:. The conversion rate was significantly better in the TACE-HAIC group than in the c-TACE group (48.8% vs 9.5%; P 0.05). Conclusions:. TACE-HAIC demonstrated a higher conversion rate and progression-free survival benefit than c-TACE and could be considered as a more effective regimen for patients with initially unresectable HCC. Future prospective randomized trials are needed to confirm it.